Form 8-K · Current Report · Filed 2026-03-09
Abbott Laboratories Completes $20 Billion Senior Notes Offering to Fund Exact Sciences Acquisition
On March 9, 2026, Abbott Laboratories issued $20 billion in senior notes to fund the acquisition of Exact Sciences Corporation.
- Filer
- Abbott Laboratories ABT · NYSE
- Filed
- Accession
- 0001104659-26-025240
- CIK
- 0000001800
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Details
The notes offering includes various maturities and interest rates, and Abbott intends to use the proceeds for the acquisition, related fees, and general corporate purposes. If the acquisition is not completed within a specified period, Abbott will redeem the notes at a premium.
Items reported
Reported Item
Market reaction
Close before filing
$109.56
Next session
+0.9%
Since filing
-3.5%
Latest close
$105.70
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ABT reporting the same item, with the next session's move:
About Abbott Laboratories
Abbott Laboratories, a globally renowned company, specializes in the development and production of healthcare and medical products. Founded in 1888 and headquartered in Abbott Park, Illinois, Abbott is a pivotal entity in the healthcare sector. The company provides essential products spanning diagnostics, medical devices, nutritional products, and branded generic pharmaceuticals. Notably, Abbott's extensive diagnostic solutions include immunoassays and molecular diagnostics, crucial for medical testing and healthcare management. Its medical devices division produces cardiovascular and neuromodulation products, enhancing patient care across diverse medical practices. Abbott’s nutritional segment, featuring well-known brands like Similac and Ensure, supports health and wellness across various demographics. Serving markets globally, Abbott Laboratories plays a critical role in advancing healthcare infrastructure and delivering innovative solutions that address evolving health challenges worldwide. As a significant player in the life sciences field, Abbott's contributions significantly influence patient outcomes and healthcare delivery systems.
Never miss another ABT filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.